Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial

Jarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah, Scott J Antonia

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

1 results
- Title(descending)

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)
Faivre-Finn, C. (Corresponding participant)
Impact: Health and wellbeing